CSE: BNXT FSE: 4XT OTCQB: XPHYF
Investing in Bionxt is an investment in the hub where pharmaceuticals meet innovation; where disruptive solutions are accelerated and commercialized to have big impact.
There is a vast portion of the pharmaceutical landscape just waiting to be explored for the next big advancement. That’s where we live. From applying psychedelics to major neurological diseases to developing rapid testing to support pandemic management, our work is all about innovation to impact.
Mar 18, 2024
Based on the recent success of its toxicity and comparative pharmacokinetic (“PK”) studies the Company is advancing towards human comparative bioavailability studies on an expedited...
Drug Delivery, Featured, Press Releases
Mar 13, 2024
The animal PK study results are highly promising and demonstrated comparable rapid absorption and systemic exposure between the Company’s ODF product and the name-brand reference...
Mar 4, 2024
BioNxt is pleased to report that the comparative pharmacokinetic study for its oral dissolvable film based proprietary Cladribine product for the treatment of Multiple Sclerosis...
Bionxt is well positioned to execute on important core milestones in all focus areas, including the commercialization of infectious disease diagnostics; the clinical validation of transdermal and sublingual drug formulations; and continued development of psychedelic medicine.
McMillan LLP
Royal Centre, Suite 1500
1055 West Georgia Street,
PO Box 11117
Vancouver, BC V6E 4N7
Canada
Davidson & Company
609 Granville Street, Suite 1200
P.O. Box 10372, Pacific Centre
Vancouver, BC V7Y 1G6
Canada
Computershare Trust
Company of Canada
510 Burrard Street
Vancouver, BC V6C 3B9
Canada
If you have specific questions, leave a note of us in the form below.
We’ll get back to you right away.
Hear about our latest research, products, exclusive partnerships & more.